This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Successfully Accessing Medical Equipment Markets In CIVETS

NEW YORK, March 28, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Successfully Accessing Medical Equipment Markets in CIVETS http://www.reportlinker.com/p01048236/Successfully-Accessing-Medical-Equipment-Markets-in-CIVETS.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply

Analysis of the health environment and commercial prospects in 6 high-growth emerging markets

For the last few years much interest and effort has been invested to better understand the first tier emerging markets of Brazil, Russia, India and China. But as that understanding matures, the spotlight is increasingly being cast on tier two markets that combine large populations with low median age, significant unmet clinical need, and rising economic performance. These markets have become known collectively since 2009 by the acronym CIVETS.

The CIVETS markets are geographically diverse but in common offer medical device and equipment manufacturers strong reliance on imports and rapid growth rates. At a time when established first-world markets are experiencing growth of 0-3% and with long-term issues around reducing sovereign debt, CIVETS such as Turkey and Indonesia are offering medical market growth rates of 7.4% and 14.5% respectively in the medium-term, albeit from a lower value base.Of course, the political and health infrastructure in many of these markets is less stable and developed, and that is why this new report from Espicom is the perfect detailed briefing of significant long-term opportunities in these countries.

Understand fully the prospects and operating environment in these key emerging markets with this excellent report service

Driven by patient populationAll markets, including health, are per capita driven. But simple per capita considerations are not sufficient to appreciate the changing health profile of a country and the demand for health services/infrastructure. Understanding these dynamics will identify the potential for suppliers of medical devices, equipment and supplies and their related supportservices.

A key aspect which links CIVETS is a growing population that is young, technologically sophisticated and consumer orientated. The median age in the 6 CIVETS markets is 27; in Egypt it is just 24. By comparison, the median ages in the US and UK are 37 and 40, respectively. This profile of large numbers of economically active individuals, along with development of diverse economic activity, often related to mineral wealth, is driving GDP up and hence the improvement in social and health provision.

65+ population group to rise slowlyAt the same time, for the medium term, the number of elderly (65+) as a % of the population will rise relatively slowly – this group places the largest demand on health services and hence its impact on health spending is significant. Compare the following stats for an example:

% of population aged over 65 by 2016 Indonesia 6.6% France 19%

While varying widely within the CIVETS group, it is fair to say that the infrastructure and provision of health services in all CIVETS has some way to go before reaching first-world standards. Beyond mostly city based hi-tech health facilities lies much unmet clinical need in poorly provided rural areas, with only the most basic support services available. A further issue to consider is the role played by aid in the development of health services.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs